TherapeuticsMD Rating Reiterated by Noble Financial (TXMD)
TherapeuticsMD (NASDAQ:TXMD)‘s stock had its “buy” rating reiterated by Noble Financial in a research note issued on Friday, Analyst RN reports.
Shares of TherapeuticsMD (NASDAQ:TXMD) opened at 5.13 on Friday. TherapeuticsMD has a one year low of $1.65 and a one year high of $5.50. The stock has a 50-day moving average of $4.82 and a 200-day moving average of $3.46. The company’s market cap is $743.7 million.
In other TherapeuticsMD news, Director Brian Bernick sold 31,250 shares of TherapeuticsMD stock on the open market in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $5.13, for a total value of $160,312.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of other firms have also recently commented on TXMD. Analysts at Cowen and Company initiated coverage on shares of TherapeuticsMD in a research note to investors on Wednesday. They set an “outperform” rating on the stock. Analysts at Stifel Nicolaus initiated coverage on shares of TherapeuticsMD in a research note to investors on Friday, November 1st. They set a “buy” rating and a $8.00 price target on the stock.
TherapeuticsMD, Inc promotes, distributes and sells certain products developed and sold by Spectrum Health Network, Inc (NASDAQ:TXMD) relative to its digital media network.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.